KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $502.1 million.

  • Halozyme Therapeutics' Retained Earnings rose 2628.51% to $502.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $502.1 million, marking a year-over-year increase of 2628.51%. This contributed to the annual value of $359.9 million for FY2024, which is 29742.57% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Retained Earnings stood at $502.1 million, which was up 2628.51% from $361.0 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Retained Earnings registered a high of $502.1 million during Q3 2025, and its lowest value of -$433.7 million during Q1 2021.
  • For the 5-year period, Halozyme Therapeutics' Retained Earnings averaged around $122.9 million, with its median value being $140.4 million (2023).
  • Data for Halozyme Therapeutics' Retained Earnings shows a peak YoY increase of 245378.0% (in 2023) and a maximum YoY decrease of 3677.43% (in 2023) over the last 5 years.
  • Halozyme Therapeutics' Retained Earnings (Quarter) stood at -$58.9 million in 2021, then soared by 343.1% to $143.2 million in 2022, then crashed by 36.77% to $90.6 million in 2023, then surged by 297.43% to $359.9 million in 2024, then skyrocketed by 39.54% to $502.1 million in 2025.
  • Its Retained Earnings was $502.1 million in Q3 2025, compared to $361.0 million in Q2 2025 and $478.0 million in Q1 2025.